Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors

被引:6
|
作者
Zhong, Xue [1 ]
Deng, Huiwen [1 ]
Long, Min [1 ]
Yin, Honglu [1 ]
Zhong, Qiu [2 ]
Zheng, Shilong [2 ]
Gong, Tao [1 ]
He, Ling [1 ]
Wang, Guangdi [2 ]
Sun, Qiu [1 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, Sichuan Res Ctr Drug Precis Ind Technol, Natl Clin Res Ctr Geriatr, Chengdu 610041, Peoples R China
[2] Xavier Univ Louisiana, RCMI Canc Res Ctr, Dept Chem, New Orleans, LA 70125 USA
[3] Sichuan Univ, West China Hosp, West China Med Publishers, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
Berberine analogs; p300; CBP HAT inhibitors; Histone acetyltransferase; HIGH EXPRESSION; ACETYLTRANSFERASE; CANCER; CBP;
D O I
10.1016/j.bioorg.2023.106597
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The protein p300 is a positive regulator of cancer progression and is related to many human pathological conditions. To find effective p300/CBP HAT inhibitors, we screened an internal compound library and identified berberine as a lead compound. Next, we designed, synthesized, and screened a series of novel berberine analogs, and discovered that analog 5d was a potent and highly selective p300/CBP HAT inhibitor with IC50 values of 0.070 mu M and 1.755 mu M for p300 and CBP, respectively. Western blotting further proved that 5d specifically decreased H3K18Ac and interfere with the function of histone acetyltransferase. Although 5d had only a moderate inhibitory effect on the MDA-MB-231 cell line, 5d suppressed the growth of 4T1 tumor growth in mice with a tumor weight inhibition ratio (TWI) of 39.7%. Further, liposomes-encapsulated 5d increased its inhibition of tumor growth to 57.8 % TWI. In addition, 5d has no obvious toxicity to the main organ of mice and the pharmacokinetic study confirmed that 5d has good absorption properties in vivo.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors
    Yang, Yaxi
    Zhang, Rukang
    Li, Zhaojun
    Mei, Lianghe
    Wan, Shili
    Ding, Hong
    Chen, Zhifeng
    Xing, Jing
    Feng, Huijin
    Han, Jie
    Jiang, Hualiang
    Zheng, Mingyue
    Luo, Cheng
    Zhou, Bing
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (03) : 1337 - 1360
  • [2] Discovery of a Potent and Selective Covalent p300/CBP Inhibitor
    Mastracchio, Anthony
    Lai, Chunqiu
    Digiammarino, Enrico
    Ready, Damien B.
    Lasko, Loren M.
    Bromberg, Kenneth D.
    McClellan, William J.
    Montgomery, Debra
    Manaves, Vlasios
    Shaw, Bailin
    Algire, Mikkel
    Patterson, Melanie J.
    Sun, Chaohong C.
    Rosenberg, Saul
    Lai, Albert
    Michaelides, Michael R.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (05): : 726 - 731
  • [3] Selective inhibition of CBP/p300 HAT
    Sarli, Vasiliki
    Giannis, Athanassios
    CHEMISTRY & BIOLOGY, 2007, 14 (06): : 605 - 606
  • [4] Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors
    Lu, Wenchao
    Xiong, Huan
    Chen, Yu
    Wang, Chen
    Zhang, Hao
    Xu, Pan
    Han, Jie
    Xiao, Senhao
    Ding, Hong
    Chen, Zhifeng
    Lu, Tian
    Wang, Jun
    Zhang, Yuanyuan
    Yue, Liyan
    Liu, Yu-Chih
    Zhang, Chenhua
    Yang, Yaxi
    Jiang, Hualiang
    Chen, Kaixian
    Zhou, Bing
    Luo, Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (20) : 5397 - 5407
  • [5] Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins
    Thomas, Junius Eugene
    Wang, Mi
    Jiang, Wei
    Wang, Meilin
    Wang, Lu
    Wen, Bo
    Sun, Duxin
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (12) : 8178 - 8199
  • [6] Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases
    Ji, Zhiqin
    Clark, Richard F.
    Bhat, Vikram
    Hansen, T. Matthew
    Lasko, Loren M.
    Bromberg, Kenneth D.
    Manaves, Vlasios
    Algire, Mikkel
    Martin, Ruth
    Qiu, Wei
    Torrent, Maricel
    Jakob, Clarissa G.
    Liu, Hong
    Cole, Philip A.
    Marmorstein, Ronen
    Kesicki, Edward A.
    Lai, Albert
    Michaelides, Michael R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 39
  • [7] Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity
    Hu, Jiankang
    Xu, Hongrui
    Wu, Tianbang
    Zhang, Cheng
    Shen, Hui
    Dong, Ruibo
    Hu, Qingqing
    Xiang, Qiuping
    Chai, Shuang
    Luo, Guolong
    Chen, Xiaoshan
    Huang, Yumin
    Zhao, Xiaofan
    Peng, Chao
    Wu, Xishan
    Lin, Bin
    Zhang, Yan
    Xu, Yong
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (09) : 6952 - 6986
  • [8] Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors
    Popp, Tobias A.
    Tallant, Cynthia
    Rogers, Catherine
    Fedorov, Oleg
    Brennan, Paul E.
    Mueller, Susanne
    Knapp, Stefan
    Bracher, Franz
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (19) : 8889 - 8912
  • [9] Targeting cancer with selective cbp/p300 bromodomain inhibitors
    Jaleel, Mahaboobi
    Senaiar, Ramesh S.
    Abbineni, Chandrasekhar
    Renukappa, Girish A.
    Mukherjee, Subhendu
    Marappan, Sivapriya
    Samiulla, D. S.
    Aravind, A. B.
    Kumar, Naveen R.
    Reddy, Venkata Siva N.
    Babu, Asha
    Srinivas, Akhila P.
    Yadlapalli, Prasad
    Tgore, Suraj
    Raghavendra, N. R.
    Naik, Chandranath D.
    Giri, Sanjeev
    Antony, Thomas
    Nellore, Kavitha
    Chelur, Shekar
    Daginakatte, Girish
    Ravanti, laura
    Myllymaki, Mikko
    Wohlfahrt, Gerd
    Mattila, Elina
    Karlsson, Stefan
    Bjorkman, Mari
    Riikonen, Reetta
    Ikonen, Tarja
    Leimu, Laura
    Malmstrom, Chira
    Korjamo, Timo
    Moilanen, Anu
    Ramachandra, Murali
    Samajdar, Susanta
    CANCER RESEARCH, 2020, 80 (16)
  • [10] Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases
    Michaelides, Michael R.
    Kluge, Arthur
    Patane, Michael
    Van Drie, John H.
    Wang, Ce
    Hansen, T. Matthew
    Risi, Roberto M.
    Mantei, Robert
    Hertel, Carmen
    Karukurichi, Kannan
    Nesterov, Alexandre
    McElligott, David
    de Vries, Peter
    Langston, J. William
    Cole, Philip A.
    Marmorstein, Ronen
    Liu, Hong
    Lasko, Loren
    Bromberg, Kenneth D.
    Lai, Albert
    Kesicki, Edward A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (01): : 28 - 33